The abstract is read at the publisher; the summary is JClub's.
An advanced HTS using engineered Toxoplasma gondii Tg68 identified 160 repurposing compounds with >80% inhibition of both tachyzoites and bradyzoites at 10 micromolar.
- Why it matters: Treatment is complicated by stage switching between actively replicating tachyzoites and semidormant bradyzoites, creating a need for drugs active across both forms.
- What they did: The ReFRAME library (14,095 molecules) was screened in 384-well assays using Tg68 expressing nano luciferase for bradyzoites and firefly luciferase for tachyzoites, then filtered using HEK293T cytotoxicity data and HepG2 CC50 <20.
- The result: Top hits inhibited intact cysts after 24 h, were mostly additive with atovaquone and pyrimethamine, and in MIR testing six of nine compounds showed no detectable parasites over 30 days.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.